Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GCK | P35557 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27109591 | 0.84 | HDAC8 (0.55) | SMN1; SMN2KDM4EGCKNPC1RAB9A | |
| SCHEMBL9170741 | 0.81 | MEN1 (0.58) | MAPTSMN1; SMN2GCKNPC1RAB9A | |
| SCHEMBL1222283 | 0.81 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL23099698 | 0.80 | NPC1 (0.67) | SMN1; SMN2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL16595775 | 0.79 | GCK (0.49) | MAPTGCKNPC1RAB9AKMT2A | |
| SCHEMBL30147470 | 0.78 | GCK (0.59) | SMN1; SMN2GCKNPC1RAB9AHDAC8 | |
| SCHEMBL1222443 | 0.77 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL8616315 | 0.76 | SMN1; SMN2 (0.56) | MAPTSMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL2563949 | 0.76 | KMT2A (0.57) | MAPTSMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL8736963 | 0.76 | MMP13 (0.56) | SMN1; SMN2KDM4EGCKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | MAPT 1355/4885SMN1; SMN2 21/4885KDM4E 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.